Background The multicenter double-blind, randomized Bergamo Nephrologic Diabetes
Complications Trial (BENEDICT) was designed to assess whether angiotensin-converting–…

Background The effects of pharmacological blood pressure lowering at normal or high-normal
blood pressure ranges in people with or without pre-existing cardiovascular disease …

Background Stratum 2 of the Ramipril Efficacy in Nephropathy (REIN) study has already
shown that in patients with chronic nephropathies and proteinuria of 3 g or more per 24 h, …

A 60-year-old man with recently diagnosed type 2 diabetes mellitus has a serum creatinine
level of 1.5 mg per deciliter (133 μmol per liter), and a dipstick test shows proteinuria (++). …

The prevalence of chronic renal disease is increasing worldwide. Most chronic nephropathies
lack a specific treatment and progress relentlessly to end-stage renal disease. However, …

Among the several theories on the pathophysiology of progressive nephropathies [1—41,
the most convincing one [1, 2] suggests that the initial reduction in nephron number …

Background The Ramipril Efficacy In Nephropathy (REIN) study found that in patients with
chronic nephropathies and proteinuria of 3 g or more per 24 h, ramipril safely reduced the rate …

Background In chronic nephropathies, inhibition of angiotensin-converting enzyme (ACE) is
renoprotective, but can further renoprotection be achieved by reduction of blood pressure to …

Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic
purpura. The term thrombotic microangiopathy (TMA) defines a lesion of vessel wall …

In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) complement
plays a primary role in disease pathogenesis. Herein we report the outcome of a 2015 …